According to a new report, published by KBV research, The Global Hemophilia Market size is expected to reach $18.3 billion by 2030, rising at a market growth of 6.2% CAGR during the forecast period.
The Specialty Pharmacies segment is leading the Global Hemophilia Market by Distribution Channel in 2022; thereby, achieving a market value of $11.3 billion by 2030. There are extremely few qualified medical practitioners who can provide hemophilia treatment because it is a rare and difficult condition. The "hemophilia treatment centers," or HTCs as they are more commonly known, are where the majority of hemophilia patients receive care. Specialty pharmacies supply the majority of the HTCs' drug needs, and the majority of them have multidisciplinary teams with extensive expertise in controlling hemophilia.
The Hemophilia B segment would witness a CAGR of 6.5% during (2023 - 2030). The introduction of gene therapy and a strong product pipeline have facilitated market expansion. Factor IX, a clotting protein, is either absent or deficient in hemophilia B, also known as factor IX (FIX) deficiency or Christmas disease. About one-third of instances are brought on by a spontaneous mutation or change in a gene, even if it is inherited from parents to offspring.
The Prophylaxis segment is generating the highest revenue in the Global Hemophilia Market by Treatment Type in 2022; thereby, achieving a market value of $9.3 billion by 2030. Treatments for prophylaxis are typically provided for serious patients. Segment expansion is being fueled by a unique method of treating patients who receive regular infusions of clotting factor concentrates.
The Gene Therapy & Monoclonal Antibodies segment is registering a CAGR of 7.3% during (2023 - 2030). Gene therapy for the treatment of hemophilia may represent a "possible breakthrough" in the medical community because it is recognized as a genetic illness. In order to replace the hemophilia patient's own defective gene, the treatment establishes continuous endogenic production of factor 8 or factor 9 after the transmission of a functional gene. Hemophilia gene therapy's potential offers hope for more people around the world to access the treatment.
The North America region dominated the Global Hemophilia Market by Region in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $8.0 billion by 2030. The Europe market is expected to witness a CAGR of 5.7% during (2023 - 2030). Additionally, The Asia Pacific market is expected to witness a CAGR of 7.4% during (2023 - 2030).
Full Report: https://www.kbvresearch.com/hemophilia-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Takeda Pharmaceutical Company Limited, CSL Limited (CSL Behring), Pfizer, Inc., Bayer AG, F. Hoffmann-La Roche Ltd., Novo Nordisk A/S, Octapharma AG, BioMarin Pharmaceutical Inc., Swedish Orphan Biovitrum AB (Investor AB) and Sanofi S.A.
By Distribution Channel
By Type
By Treatment Type
By Therapy
By Geography
Companies Profiled
Unique Offerings 
